Globe Newswire
CALGARY, May 23, 2024 (GLOBE NEWSWIRE) -- Tornado Global Hydrovacs Ltd. (“Tornado” or the “Company”) (TSX-V: TGH; OTCQX: TGHLF) today reported its unaudited condensed consolidated financial results for the three months period ended March 31, 2024. The unaudited condensed consolidated financial statements and related management discussion and analysis are available on the Company’s issuer profile in Canada on SEDAR+ at www.sedarplus.com, the United States at ... (continue reading...)
TORONTO, May 23, 2024 (GLOBE NEWSWIRE) -- Jamieson Wellness Inc. (“Jamieson Wellness” or the “Company”) (TSX: JWEL) announced today that each of the nominee directors listed in the management information circular of the Company dated March 11, 2024 was elected as a director of the Company (a “Director”) at the annual meeting (the “Meeting”) of the holders of common shares of the Company (the “Common Shares”) held today. The number of Common Shares... (continue reading...)
SHENZHEN, China, May 23, 2024 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading technology-empowered personal financial service enabler in China, today announced its unaudited financial results for the quarter ended March 31, 2024.
“In the first quarter of 2024, Lexin reported total loan origination of RMB58.0 billion, a decrease of 4.8% year-over-year, reflecting a strategy of controlled growth. The... (continue reading...)
Toronto, May 23, 2024 (GLOBE NEWSWIRE) -- Restaurants Canada is deeply concerned about the increase in the price of live BC chicken, approved by the BC Farm Industry Review Board. This decision will have significant consequences for British Columbia restaurants and consumers who value chicken as an affordable food choice. British Columbians already pay the highest retail price for chicken in the country, 40% higher than the Canadian average. While there are several... (continue reading...)
SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired AXT, Inc. (NASDAQ: AXTI) securities between March 24, 2021 and April 3, 2024. AXT, Inc. describes itself as a “worldwide materials science company that develops and produces high-performance compound and single element semiconductor substrates, also known as wafers."
For... (continue reading...)
More Globe Newswire
View Older Stories-
Mediacom Communications Ready to Connect Customers in First Phase of 221-Mile Seminole County Fiber Network Buildout
-
Western Pacific Trust Company Announces Q1-2024 Results
-
The Dominican Republic and Purdue University Sign MOU to Drive Semiconductor Growth
-
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
-
Associa Recognized as a US Best Managed Company
-
Huize Holding Limited Reports First Quarter 2024 Unaudited Financial Results
-
Gildan Board of Directors Resigns
-
Acceleware Ltd. Reports First Quarter 2024 Financial and Operating Results
-
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti
-
Parks! America, Inc. Announces Glass Lewis Recommends Parks! America Shareholders Vote “FOR” Each of the Director Nominees Recommended by the Board
-
CORRECTION – The Herzfeld Caribbean Basin Fund, Inc. Announces Distribution in Stock and Cash
-
Mountain America Credit Union Named Utah's Leading SBA Lender for Third Consecutive Year
-
Stockholder Alert: Robbins LLP Informs Investors that a Class Action has been filed Against Cambium Networks Corporation (CMBM)
-
3Daughters to Participate in Women’s Health Panel During the 2024 BIO International Convention in San Diego, CA, June 3-6
-
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
-
Premier Health Reports 2024 Second Quarter Results
-
Titanium Transportation Group Declares Quarterly Dividend
-
ALT Stockholders: Robbins LLP Reminds ALT Stockholders of Securities Fraud Class Action Against Altimmune, Inc.
-
MTTR Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Matterport to CoStar Group
-
MTTR Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Matterport to CoStar Group
-
HRBR Stockholders: Robbins LLP Reminds HRBR Stockholders of Securities Fraud Class Action Against Harbor Diversified, Inc.
-
DOCS INVESTOR NEWS: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCS
-
Trailblazing Dragons' Den Star Named United Nations Association in Canada's 2024 Global Citizen Laureate
-
INTC Stockholders: Robbins LLP Reminds INTC Stockholders of Securities Fraud Class Action Against Intel Corporation
-
Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
-
Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
-
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Special Olympics Florida and Orlando Health Announce Five-Year Partnership
-
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
-
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
-
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
-
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
-
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (m
-
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
-
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the
-
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
-
Elcora Announces Share Consolidation
-
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinica
-
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
-
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
-
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meet
-
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST
-
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
-
Timbercreek Financial Declares May 2024 Dividend
-
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
-
Canadian Premium Sand Inc. Announces Second Quarter 2024 Results
-
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting